Skip to content
value.today
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc.

CRDF
$71 Mmarket cap on Oct 30, 2026-4.3% since Jan 2024
Compare
World rank
#20,040
Revenue
$1 M
For year ending December-2025
Net income
$-46 M
-7771.2% margin
SEC filing
Employees
—

Cardiff Oncology, Inc. in brief

Cardiff Oncology, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $71 M on 30 October 2026, which makes it the 20,040th largest listed company in the world and the 3,703rd largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $46 M. Mani Mohindru is its chief executive. Its shares trade under the symbol CRDF (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Cardiff Oncology, Inc.

Trovagene changed the name of company to Cardiff Oncology. Cardiff Oncology is clinical-state biotechnology company with headquarters is in USA.

Cardiff Oncology is a clinical-stage company with the singular mission of developing new treatment options for cancer patients. Their goal is to overcome resistance, extend duration of response and increase overall survival.

Cardiff Oncology, Inc. timeline

5 events, 2003–2024
  1. 2003
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2004
  4. ✎
    Renamed Xenomics Inc
    Formerly Used Kar Parts Inc.
  5. 2009
  6. ✎
    Renamed TrovaGene Inc.
    Formerly Xenomics Inc.
  7. 2020
  8. ✎
    Renamed Cardiff Oncology, Inc.
    Formerly TrovaGene Inc..
  9. 2024
  10. 💰
    Record revenue of $1 million
    FY2024, the highest of the 8 years on record.

Events of Cardiff Oncology, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$156 M$312 M$468 M$624 M2020202120222023202420252026

World rank over time

▲ up 6,354 places since 2020
2020-01-01: #26438#26,43820202021-01-01: #10477#10,47720212022-01-07: #17310#17,31020222022-12-25: #24616#24,61620222023-07-30: #23376#23,37620232024-01-05: #23056#23,05620242026-03-08: #9604#9,60420262026-08-01: #18241#18,24120262026-10-14: #19725#19,72520262026-10-30: #20084#20,0842026

Rank in USA: #4,672 (Jan 2020) · #2,632 (Jan 2021) · #3,588 (Jan 2022) · #4,707 (Dec 2022) · #4,489 (Jul 2023) · #3,884 (Jan 2024) · #1,859 (Mar 2026) · #3,579 (Aug 2026) · #3,624 (Oct 2026) · #3,707 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
128.7×
Price / book
1.6×
Free cash flow yield
-53.6%
Net margin (TTM)
-6845.5%
Operating margin
-8298.3%
Return on equity
-82.9%
Liabilities / assets
26.7%
Net debt
$-8M
Revenue growth
-13.2%
R&D / revenue
5988.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $0M, net income $-16M$0MFY18Fiscal year ending Dec 2019: revenue $0M, net income $-16M$0MFY19Fiscal year ending Dec 2020: revenue $0M, net income $-19M$0MFY20Fiscal year ending Dec 2021: revenue $0M, net income $-28M$0MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-39M$0MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-41M$0MFY23Fiscal year ending Dec 2024: revenue $1M, net income $-45M$1MFY24Fiscal year ending Dec 2025: revenue $1M, net income $-46M$1MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$1M-13.2%$-49M$-46M-7771.2%
Dec 2024$1M+38.8%$-49M$-45M-6680.9%
Dec 2023$0M+25.6%$-45M$-41M-8457.1%
Dec 2022$0M+8.3%$-40M$-39M-9923.1%
Dec 2021$0M-2.7%$-29M$-28M-7858.3%
Dec 2020$0M+54.2%$-19M$-19M-5218.9%
Dec 2019$0M-36.8%$-17M$-16M-6837.5%
Dec 2018$0M—$-17M$-16M-4331.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-38M$0M$-38M$-0.69—
Dec 2024$-38M$0M$-38M$-0.95—
Dec 2023$-31M$1M$-31M$-0.93—
Dec 2022$-34M$1M$-35M$-0.89—
Dec 2021$-23M$0M$-23M$-0.73—
Dec 2020$-16M$0M$-17M$-1.08—
Dec 2019$-13M$0M$-13M$-2.80—
Dec 2018$-13M$0M$-13M$-8.26—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$1M
Net income, trailing 12 months
$-38M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $0M, net income $-12M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-13M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-14M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-11M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-7M$0MDec ’25Three months to Mar 2026: revenue $0M, net income $-12M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-9M$0MJun ’26Three months to Sep 2026: revenue $0M, net income $-9M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M (+41.7% on a year earlier), net income $-9M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Cardiff Oncology, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-49 M
Net income
$-46 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$62 M
Total liabilities
$17 M
Total equity
$45 M

As of December-2025

Top 75 institutional investors in Cardiff Oncology, Inc.#

As of Sep 30, 2026
75 institutions held 18.0 M shares (about 23.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 18.0%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Cardiff Oncology, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Laurion Capital Management LP3,098,2990 (0.00%)3.98%$4 MOct 30, 2026
2Vanguard Capital Management LLC2,867,865-27,727 (-0.96%)3.69%$3 MNov 13, 2026
3Pfizer Inc2,411,5750 (0.00%)3.10%$3 MNov 12, 2026
4Franklin Templeton Inc1,205,8030 (0.00%)1.55%$1 MNov 12, 2026
5BlackRock, Inc.935,893-36,980 (-3.80%)1.20%$1 MNov 13, 2026
6Blair William & Co/il916,975+4,462 (+0.49%)1.18%$1 MNov 10, 2026
7Geode Capital Management, LLC839,868+19,806 (+2.42%)1.08%$1 MNov 6, 2026
8GoalVest Advisory LLC687,285New0.88%$1 MOct 2, 2026
9Gsa Capital Partners LLP537,602+364,328 (+210.26%)0.69%$1 MNov 16, 2026
10Vanguard Fiduciary Trust Co476,825+66,223 (+16.13%)0.61%$1 MNov 13, 2026
11Balyasny Asset Management L.P.381,940New0.49%$0 MNov 16, 2026
12State Street Corp324,095-7,300 (-2.20%)0.42%$0 MNov 12, 2026
13Two Sigma Investments, LP321,831+274,165 (+575.18%)0.41%$0 MNov 16, 2026
14UBS Group AG300,156-338,543 (-53.01%)0.39%$0 MNov 10, 2026
15BNP Paribas Financial Markets228,289-172 (-0.08%)0.29%$0 MNov 12, 2026
16Susquehanna International Group, LLP218,495+102,357 (+88.13%)0.28%$0 MNov 16, 2026
17X-Square Capital, LLC205,7000 (0.00%)0.26%$0 MNov 10, 2026
18Morgan Stanley180,632-65,463 (-26.60%)0.23%$0 MNov 13, 2026
19Bank of New York Mellon Corp161,6890 (0.00%)0.21%$0 MNov 5, 2026
20Goldman Sachs Group Inc155,143+34,316 (+28.40%)0.20%$0 MNov 16, 2026
21Northern Trust Corp152,8750 (0.00%)0.20%$0 MNov 16, 2026
22Millennium Management LLC116,375-18,142 (-13.49%)0.15%$0 MNov 16, 2026
23AlphaCore Capital LLC108,426-67 (-0.06%)0.14%$0 MNov 4, 2026
24Marshall Wace, LLP108,099-54,115 (-33.36%)0.14%$0 MNov 13, 2026
25Jane Street Group, LLC78,228-529,672 (-87.13%)0.10%$0 MNov 12, 2026
Show all 75: investors 26 to 75
Institutional investors 26 to 75 in Cardiff Oncology, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Assenagon Asset Management S.A.67,231-67,231 (-50.00%)0.09%$0 MOct 15, 2026
27XTX Topco Ltd62,681-34,719 (-35.65%)0.08%$0 MNov 16, 2026
28Qube Research & Technologies Ltd59,359-66,191 (-52.72%)0.08%$0 MNov 13, 2026
29AQR Capital Management LLC53,376-292,977 (-84.59%)0.07%$0 MNov 16, 2026
30Renaissance Technologies LLC51,800+37,858 (+271.54%)0.07%$0 MNov 12, 2026
31Capstone Investment Advisors, LLC51,1900 (0.00%)0.07%$0 MNov 16, 2026
32Elkhorn Partners Limited Partnership48,0000 (0.00%)0.06%$0 MNov 13, 2026
33Creative Planning47,287-810 (-1.68%)0.06%$0 MNov 2, 2026
34Glenview Trust Co43,1280 (0.00%)0.06%$0 MOct 28, 2026
35HighTower Advisors, LLC34,206-558 (-1.61%)0.04%$0 MNov 10, 2026
36Mariner, LLC26,099-23,257 (-47.12%)0.03%$0 MNov 12, 2026
37Vanguard Global Advisers, LLC25,2710 (0.00%)0.03%$0 MNov 13, 2026
38Rockefeller Capital Management L.P.25,000+5,000 (+25.00%)0.03%$0 MNov 13, 2026
39Tamar Securities, LLC23,7950 (0.00%)0.03%$0 MNov 3, 2026
40Royal Bank Of Canada23,721+11,399 (+92.51%)0.03%$0 MNov 16, 2026
41Dimensional Fund Advisors LP23,369-13,281 (-36.24%)0.03%$0 MNov 4, 2026
42Integrity Alliance, LLC.22,860+10,000 (+77.76%)0.03%$0 MOct 29, 2026
43Post Resch Tallon Group Inc.22,5150 (0.00%)0.03%$0 MOct 9, 2026
44R Squared Ltd22,269+251 (+1.14%)0.03%$0 MNov 6, 2026
45Raymond James Financial Inc22,172-500 (-2.21%)0.03%$0 MNov 12, 2026
46PFG Investments, LLC20,5010 (0.00%)0.03%$0 MNov 12, 2026
47Baker Ellis Asset Management LLC20,0000 (0.00%)0.03%$0 MOct 14, 2026
48Proactive Wealth Strategies LLC20,0000 (0.00%)0.03%$0 MNov 9, 2026
49Brighton Jones LLC16,741-3,712 (-18.15%)0.02%$0 MNov 3, 2026
50Capital Advisors Wealth Management, LLC15,5250 (0.00%)0.02%$0 MOct 9, 2026
51Wells Fargo & Company/mn15,1300 (0.00%)0.02%$0 MNov 16, 2026
52MAI Capital Management14,576-8,797 (-37.64%)0.02%$0 MNov 12, 2026
53Gladstone Institutional Advisory LLC13,0000 (0.00%)0.02%$0 MNov 13, 2026
54FMR LLC11,611+1,818 (+18.56%)0.01%$0 MNov 10, 2026
55Ledgewood Wealth Advisors, LLC11,1900 (0.00%)0.01%$0 MOct 9, 2026
56Security National Bank9,7670 (0.00%)0.01%$0 MOct 26, 2026
57Trust Co Of Toledo NA /oh/9,0000 (0.00%)0.01%$0 MOct 16, 2026
58Golden State Wealth Management, LLC7,100+50 (+0.71%)0.01%$0 MNov 2, 2026
59Federated Hermes, Inc.4,232-579 (-12.03%)0.01%$0 MNov 12, 2026
60IFP Advisors, Inc3,859+19 (+0.49%)0.01%$0 MOct 16, 2026
61US Bancorp \de\3,1090 (0.00%)0.00%$0 MNov 5, 2026
62Farther Finance Advisors, LLC2,696-183 (-6.36%)0.00%$0 MOct 8, 2026
63Arax Advisory Partners1,993-5,688 (-74.05%)0.00%$0 MNov 12, 2026
64Jpmorgan Chase & Co1,554-361 (-18.85%)0.00%$0 MNov 12, 2026
65Jones Financial Companies Lllp1,000+950 (+1900.00%)0.00%$0 MNov 13, 2026
66Clearstead Advisors, LLC7000 (0.00%)0.00%$0 MNov 6, 2026
67Essential Partners LLC561-1,524 (-73.09%)0.00%$0 MOct 14, 2026
68Fortitude Family Office, LLC165-214 (-56.46%)0.00%$0 MOct 14, 2026
69SBI Securities Co., Ltd.146+1 (+0.69%)0.00%$0 MOct 22, 2026
70NewEdge Advisors, LLC810 (0.00%)0.00%$0 MNov 13, 2026
71Northwestern Mutual Wealth Management Co480 (0.00%)0.00%$0 MNov 13, 2026
72Parallel Advisors, LLC350 (0.00%)0.00%$0 MNov 3, 2026
73SJS Investment Consulting Inc.9-54 (-85.71%)0.00%$0 MOct 26, 2026
74Barclays PLC5-5,402 (-99.91%)0.00%$0 MNov 6, 2026
75ROSS\JOHNSON & Associates LLC10 (0.00%)0.00%$0 MNov 16, 2026

Mutual funds holding Cardiff Oncology, Inc.#

36 funds hold shares worth $7 M (about 6.2% of the company). Since their previous reports 15 added shares and 50 sold, selling $6 M net.
Mutual funds holding Cardiff Oncology, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.2.07 M$3 M2.7%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.759,321$1 M0.98%<0.01%+5.8%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC363,388$1 M0.47%<0.01%+1.8%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.324,898$1 M0.42%<0.01%+6.0%May 31, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.438,961$0 M0.56%0.03%no changeJul 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors221,689$0 M0.28%0.02%+39%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC114,137$0 M0.15%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC100,743$0 M0.13%<0.01%+7.6%May 31, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.72,057$0 M0.09%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC34,646$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.46,242$0 M0.06%<0.01%+54%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.28,295$0 M0.04%<0.01%+3.0%May 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.25,068$0 M0.03%<0.01%+4.8%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.35,418$0 M0.05%<0.01%−5.4%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company23,843$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.27,727$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC30,591$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC16,918$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC22,892$0 M0.03%<0.01%+6.0%Jul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC15,011$0 M0.02%<0.01%+25%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION7,300$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC13,515$0 M0.02%<0.01%+27%Jul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC6,166$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.3,969$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC5,115$0 M<0.01%<0.01%+21%Jun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP7,385$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.7,233$0 M<0.01%<0.01%+1.4%Jul 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC2,955$0 M<0.01%<0.01%+10%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC2,310$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC2,331$0 M<0.01%<0.01%−39%May 31, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC1,935$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC1,563$0 M<0.01%<0.01%−5.1%May 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC1,854$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC1,791$0 M<0.01%<0.01%−66%Jun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,435$0 M<0.01%<0.01%+16%Jun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust542$0 M<0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 36 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Cardiff Oncology, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$1.1 M
4 purchases, 2 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$1.1 M
open market only
Insiders on file
21
since
$1.1 M$0Nov 2023: bought $22 K (1 trades), sold $0 (0 trades)Nov 23Dec 2023: bought $41 K (1 trades), sold $0 (0 trades)DecDec 2024: bought $1.0 M (6 trades), sold $0 (0 trades)DecJul 2025: bought $711 K (2 trades), sold $0 (0 trades)JulJun 2026: bought $66 K (2 trades), sold $0 (0 trades)JunJul 2026: bought $1.1 M (2 trades), sold $0 (0 trades)Jul
Bought (open market)Sold (open market)Hover a month for the totals
Cardiff Oncology, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Gary W. PaceDirectorBuy+687,285$1.460$1.0 M2.04 MForm 4
filed Mani MohindruChief Executive Officer, DirectorBuy+34,364$1.460$50 K59,067Form 4
filed Mani MohindruChief Executive Officer, DirectorBuy+24,703$1.210$30 K24,703Form 4
filed Gary W. PaceDirectorBuy+30,000$1.220$37 K1.36 MForm 4
filed Gary W. PaceDirectorBuy+275,000$2.450$674 K1.33 MForm 4
filed Gary W. PaceDirectorBuyindirect+15,000$2.450$37 K1.35 MForm 4
filed James E. LevineChief Financial OfficerBuyindirect+2,400$5.000$12 K67,716Form 4
filed James E. LevineChief Financial OfficerBuyindirect+2,752$5.420$15 K65,316Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Cardiff Oncology, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
12.3 M
18.0% of shares · 30.82 days to cover
Buybacks, Q1 2014
$0M
Q1 2014
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-6 reverse split

Cardiff Oncology, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q1 2014Q1 2014$0M
Q4 2013Q4 2013$0M
Q3 2013Q3 2013$0M
Q2 2013Q2 2013$0M
Q1 2013Q1 2013$0M
Q4 2012Q4 2012$0M
Q3 2012Q3 2012$0M
Q2 2012Q2 2012$0M

Fails to deliver

  • : 199 shares at $0.91
  • : 41 shares at $0.88
  • : 4,982 shares at $0.94
  • : 47,210 shares at $0.89
  • : 18,173 shares at $0.97

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Cardiff Oncology, Inc. scorecard#

Passes 2 of the 15 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.6×Price to book 1.6× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median128.7×Price to sales 128.7× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-53.6%Free cash flow is -53.6% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 3
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.69 vs -0.95Diluted EPS -0.69 in fiscal 2025 against -0.95 the year before (report's currency).
    • ✗Net income higher than five years earlier-$46 M-$46 M in fiscal 2025 against -$19 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$46 MNet income -$46 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-71.5%-71.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities3.7×Current ratio 3.67 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-8.91Z-score -8.91 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year40.3%Diluted shares up 40.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Cardiff Oncology, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Cardiff Oncology, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0.60.70.50.40.40.40.20.40.50.4
Cost of revenue——————00.61.81.7
Research and development353733271711118.27.915
Selling, general and administrative14121313128.2r5.88.014—
Selling and marketing————————2.712
General and administrative————————1111
Operating expenses504946402919r17172641
Operating income−49−49−45−40−29−19r−17−17−26−40
Interest and finance income3.13.34.11.60.30.1r0.20.20.10.3
Interest expense and finance costs————00.0r00.01.01.7
Net interest income—————————−1.4
Other non-operating income (expense)3.13.24.01.20.6−0.2————
Income before tax−46−45————————
Income tax0000000000
Net income attributable to shareholders−46−45−41−39−28−19r−16−16−25−39
Earnings per share, basic-0.69-0.95-0.93-0.89-0.73-1.08-2.80-8.26-51.76r-1.30
Earnings per share, diluted-0.69-0.95-0.93-0.89-0.73-1.08-2.80-8.26-51.76r-1.37
Shares, weighted average (basic)6748454439216.02.30.5r30
Shares, weighted average (diluted)674845443921r6.02.30.5r30
Balance sheet
Cash and cash equivalents1751221612131r10118.214
Short-term investments414053891290——024
Receivables0.20.80.30.80.50.3r0.20.20.10.1
Other current assets——2.35.24.82.1r1.01.11.21.0
Current assets609577111146133r11139.539
Property, plant and equipment0.60.91.21.30.40.6r0.91.32.43.8
Right-of-use (leased) assets0.61.21.72.32.80.3r0.70——
Total assets629782116150135r13141244
Accounts payable8.14.82.02.01.41.4r0.70.70.81.1
Debt due within a year———————01.32.4
Current liabilities1613107.86.66.1r4.82.9r3.97.8
Long-term debt————————014
Lease liabilities (non-current)0.10.81.52.02.60.0r0.90——
Total liabilities1614129.89.16.6r5.84.15.824
Retained earnings−430−384−340−298−260−231r−209−192−173−148
Shareholders' equity458370106140128r7.3r106.520
Total liabilities and equity629782116150135r13141244
Shares outstanding686745454237r8.6r3.8r0.7r31
Cash-flow statement
Depreciation and amortization0.40.40.40.20.50.5r0.50.91.21.1
Share-based compensation5.74.84.54.33.21.8r0.92.24.07.5
Cash from operating activities−38−38−31−34−23−16r−13−13−23−31
Capital expenditure−0.0−0.1−0.6−1.0−0.2−0.2r−0.1−0.0−0.1−0.8
Cash from investing activities1.3143638−131−0.2r−0.10.024−25
Debt issued————00.30—07.8
Debt repaid———————0−15−8.9
Shares issued053—034112r8.812r122.4r
Cash from financing activities2.65400.135137r1216−6.42.3
Exchange-rate effect on cash———————00.0−0.0
Change in cash−34305.34.4−119121r−1.33.2——
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Cardiff Oncology, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 5 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 9

Cardiff Oncology, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officersBylaws or fiscal year changed8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Material agreement8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Directors and officersMaterial agreement8-K
Acquisition or sale completed8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Material agreement8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Cardiff Oncology, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2020$14 MPrivate placement after listing$10 to $50 million3equity, optionsSEC
May 2020$3 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Mar 2020$2 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Oct 2019$5 MPrivate placement after listing$2 to $10 million2equity, optionsSEC
Aug 2019$2 MPrivate placement after listingUnder $2 million1equity, optionsSEC
May 2019$2 MPrivate placement after listingUnder $2 million1equity, optionsSEC
Apr 2019$2 MPrivate placement after listingUnder $2 million1equity, optionsSEC
Nov 2012$4 MNo. 2$2 to $10 million8equity, optionsSEC
Jun 2009$7 MNo. 1$2 to $10 million40equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Cardiff Oncology, Inc. compares in Biotechnology

  • Market cap$71 M · higher than 31% of 726
  • Revenue$1 M · higher than 22% of 647
  • Revenue growth-13.2% · higher than 32% of 438
  • Price / sales128.7× · lower than 8% of 339
  • Price / book1.6× · lower than 65% of 534
  • FCF yield-53.6% · higher than 22% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Cardiff Oncology, Inc.🇺🇸$71 M——-13.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Cardiff Oncology, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Cardiff Oncology, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Cardiff Oncology, Inc.? Suggest a correction